| 1352 |
National Cancer Institute |
Html |
en |
Bladder Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of bladder cancer. |
| bladder infections | 0.409188 |
| cancer spreads | 0.362526 |
| body | 0.421643 |
| type | 0.363946 |
| transitional cell carcinoma | 0.368057 |
| Partial cystectomy | 0.367914 |
| following PDQ summaries | 0.361033 |
| PDQ cancer information | 0.437047 |
| cancer increases | 0.35829 |
| clinical trial search | 0.428286 |
| bladder cancer | 0.996648 |
| clinical trials | 0.716737 |
| stage IV bladder | 0.400568 |
| cancer information summary | 0.412718 |
| clinical trial | 0.562865 |
| Institute about bladder | 0.388854 |
| breast cancer prevention | 0.364729 |
| superficial bladder cancer | 0.471082 |
| patients | 0.385176 |
| treatment clinical trial | 0.370642 |
| PDQ Adult Treatment | 0.359776 |
| NCI PDQ cancer | 0.382156 |
| lymph nodes | 0.358627 |
| radiation therapy | 0.477016 |
| Treatment Editorial Board | 0.366853 |
|
| metastatic bladder cancer | 0.451959 |
| General information | 0.370997 |
| general cancer information | 0.374576 |
| treatment | 0.542299 |
| cancer prevention | 0.364857 |
| new cancer treatments | 0.373348 |
| Recurrent bladder cancer | 0.48553 |
| NCI-supported cancer | 0.389073 |
| Cancer Information Service | 0.375145 |
| urinary diversion | 0.368656 |
| invasive bladder cancer | 0.467339 |
| treatment clinical trials | 0.395244 |
| National Cancer Institute | 0.448421 |
| radical cystectomy | 0.396674 |
| new treatment | 0.433088 |
| External radiation therapy | 0.441508 |
| Bladder Cancer Treatment | 0.456321 |
| Cancer Care page | 0.36454 |
| Blood. The cancer | 0.364373 |
| bladder cancer cells | 0.466875 |
| cancer research process | 0.367381 |
| cancer clinical trials | 0.446025 |
| cancer information summaries | 0.373713 |
| comprehensive cancer information | 0.373405 |
|
CLICK HERE |
| 1592 |
National Cancer Institute |
Html |
en |
Thymoma and Thymic Carcinoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of thymoma and thymic carcinoma. |
| cancer treatment | 0.359999 |
| malignant tumor cells | 0.342024 |
| body | 0.355156 |
| type | 0.305883 |
| PDQ cancer information | 0.433839 |
| clinical trial search | 0.425022 |
| cancer cell | 0.325256 |
| thymic carcinoma cells | 0.326827 |
| clinical trials | 0.988832 |
| thymoma | 0.371455 |
| cancer information summary | 0.383363 |
| clinical trial | 0.804071 |
| patients | 0.340124 |
| earlier clinical trials | 0.306378 |
| thymic carcinoma spreads | 0.306453 |
| treatment clinical trial | 0.327343 |
| PDQ Adult Treatment | 0.30754 |
| NCI PDQ cancer | 0.333099 |
| radiation therapy | 0.826788 |
| Treatment Editorial Board | 0.331284 |
| thymic carcinomas | 0.308782 |
| General information | 0.310597 |
| general cancer information | 0.312288 |
| thymic carcinoma | 0.970766 |
| treatment | 0.610928 |
|
| new ways | 0.369751 |
| anticancer drugs | 0.338472 |
| new cancer treatments | 0.318168 |
| NCI-supported cancer | 0.344007 |
| cancer cells | 0.453663 |
| Cancer Information Service | 0.312701 |
| treatment clinical trials | 0.363023 |
| thymic carcinoma look | 0.319623 |
| National Cancer Institute | 0.457133 |
| tumor cells | 0.34225 |
| normal cells | 0.313543 |
| new treatment | 0.393453 |
| new combinations | 0.333745 |
| Blood. The cancer | 0.306577 |
| metastatic tumor | 0.308755 |
| PDQ summary | 0.316304 |
| cancer clinical trials | 0.447345 |
| stage | 0.3338 |
| tumor | 0.364487 |
| cancer information summaries | 0.310618 |
| comprehensive cancer information | 0.311036 |
| Thymic Carcinoma Treatment | 0.323064 |
| cancer | 0.980046 |
| standard treatment | 0.319507 |
|
CLICK HERE |
| 1639 |
National Cancer Institute |
Html |
en |
Laetrile/Amygdalin (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer. |
| cancer treatment | 0.438388 |
| cervical cancer cells | 0.371507 |
| PDQ cancer information | 0.581258 |
| Cancer Complementary | 0.379362 |
| clinical trials | 0.679597 |
| cancer information summary | 0.498013 |
| alternative cancer therapies | 0.390365 |
| prostate cancer cells | 0.371683 |
| CAM cancer research | 0.368282 |
| patented Laetrile | 0.633733 |
| stomach cancer patient | 0.364287 |
| patients | 0.536772 |
| cancer patients | 0.418354 |
| NCI PDQ cancer | 0.43909 |
| cancer information database | 0.387329 |
| colon cancer cells | 0.371605 |
| Therapies Editorial Board | 0.387373 |
| metabolic therapy program | 0.390038 |
| cancer cell blockers | 0.374799 |
| cancer information | 0.599008 |
| intravenous Laetrile | 0.592397 |
| laboratory study | 0.361622 |
| cancer prevention | 0.356496 |
| United States | 0.577981 |
|
| Complementary Therapies Editorial | 0.420338 |
| Drug Administration | 0.401022 |
| Cancer Information Specialist | 0.378718 |
| cancer cells | 0.467012 |
| Cancer Information Service | 0.494306 |
| laetrile breaks | 0.600513 |
| chemical amygdalin | 0.44529 |
| tumor size | 0.381862 |
| treatment clinical trials | 0.357955 |
| National Cancer Institute | 0.807094 |
| studies | 0.358599 |
| laetrile treatment | 0.698121 |
| alternative medicine | 0.450551 |
| amygdalin therapy | 0.422594 |
| Federal Trade Commission | 0.354832 |
| new treatment | 0.383104 |
| amygdalin | 0.621984 |
| Cancer Care page | 0.354541 |
| case reports | 0.418082 |
| alternative therapies | 0.420918 |
| hydrogen cyanide | 0.363445 |
| cancer information summaries | 0.388577 |
| laetrile | 0.967938 |
| cancer | 0.903387 |
|
CLICK HERE |
| 1652 |
National Cancer Institute |
Html |
en |
PC-SPES (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of PC-SPES as a treatment for prostate cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| cancer treatment | 0.437115 |
| cancer prevention | 0.282542 |
| Complementary Therapies Editorial | 0.411772 |
| United States | 0.349637 |
| Drug Administration | 0.423619 |
| Cancer Information Specialist | 0.306354 |
| PC-SPES | 0.776503 |
| Cancer Information Service | 0.45748 |
| PDQ cancer information | 0.587454 |
| Cancer Complementary | 0.346119 |
| CAM therapies | 0.322693 |
| treatment clinical trials | 0.274541 |
| National Cancer Institute | 0.691988 |
| clinical trials | 0.701375 |
| alternative medicine | 0.539683 |
| PC-SPES lowers PSA | 0.309751 |
| U.S. Food | 0.291013 |
| conventional treatment | 0.269047 |
| health care | 0.271323 |
| cancer information summary | 0.466619 |
| alternative cancer therapies | 0.329832 |
| Federal Trade Commission | 0.302224 |
| National Institutes | 0.284819 |
| cancer cells | 0.400978 |
|
| clinical trial | 0.31949 |
| National Center | 0.264606 |
| prostate cancer cells | 0.342551 |
| CAM cancer research | 0.300048 |
| breast cancer prevention | 0.277639 |
| cancer patients | 0.279371 |
| Cancer Care page | 0.279808 |
| prostate specific antigen | 0.386617 |
| traditional Chinese medicine | 0.370287 |
| health | 0.346702 |
| NCI’s PDQ | 0.273024 |
| PDQ summary | 0.278148 |
| Integrative Health | 0.265541 |
| NCI PDQ cancer | 0.391945 |
| cancer information database | 0.323738 |
| prostate cancer | 0.519752 |
| effects | 0.26747 |
| prescription medicines | 0.565306 |
| alternative therapies | 0.390035 |
| cancer information summaries | 0.324417 |
| Therapies Editorial Board | 0.356431 |
| cancer | 0.944963 |
| prostate problems | 0.265671 |
|
CLICK HERE |
| 1690 |
National Cancer Institute |
Html |
en |
Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pheochromocytoma and paraganglioma. |
| cancer treatment | 0.520384 |
| malignant tumor cells | 0.51392 |
| inherited pheochromocytoma | 0.499674 |
| metastatic pheochromocytoma | 0.559666 |
| catecholamine levels | 0.546812 |
| recurrent pheochromocytoma | 0.523941 |
| body | 0.55921 |
| PDQ cancer information | 0.583541 |
| clinical trial search | 0.545652 |
| clinical trials | 0.955841 |
| adrenal gland | 0.817016 |
| cancer information summary | 0.547255 |
| clinical trial | 0.684878 |
| blood pressure | 0.689096 |
| entire adrenal gland | 0.501423 |
| detailed pictures | 0.500985 |
| patients | 0.570303 |
| pheochromocytoma | 0.843137 |
| blood vessels | 0.513601 |
| PDQ Pheochromocytoma | 0.514265 |
| NCI PDQ cancer | 0.498564 |
| lymph nodes | 0.51055 |
| radiation therapy | 0.504762 |
| tyrosine kinase inhibitor | 0.539116 |
|
| benign pheochromocytoma | 0.496121 |
| treatment | 0.708415 |
| general information | 0.506946 |
| magnetic resonance imaging | 0.497402 |
| cancer cells | 0.57041 |
| adrenal cortex | 0.501382 |
| adrenal medulla | 0.501576 |
| multiple endocrine neoplasia | 0.503339 |
| treatment clinical trials | 0.532049 |
| National Cancer Institute | 0.548616 |
| tumor cells | 0.524483 |
| new treatment | 0.564593 |
| heart rate | 0.509798 |
| pheochromocytoma spreads | 0.501294 |
| pheochromocytoma cells | 0.532172 |
| Pheochromocytoma forms | 0.519073 |
| adrenal glands | 0.85433 |
| nuclear magnetic resonance | 0.499251 |
| paraganglioma | 0.578972 |
| tumors | 0.523973 |
| cancer clinical trials | 0.561663 |
| high blood pressure | 0.675166 |
| tumor | 0.650897 |
| cancer | 0.88724 |
|
CLICK HERE |
| 1940 |
National Cancer Institute |
Html |
es |
La espiritualidad en el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la influencia que tiene la espiritualidad y la religión en las personas que tienen cáncer. Se discuten varios métodos sobre manejo e intervención. |
| enfermos ayuda | 0.452293 |
| La espiritualidad | 0.924579 |
| términos espiritualidad | 0.486044 |
| siguientes aspectos | 0.444194 |
| Physician Data Query | 0.534722 |
|
| National Cancer Institute | 0.427034 |
| siguientes riesgos | 0.41834 |
| libre uso | 0.416111 |
| siguientes maneras | 0.524006 |
| Instituto Nacional | 0.45946 |
|
CLICK HERE |
| 1947 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de laringe (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de laringe. |
| glándula tiroides | 0.639428 |
| HemilaringectomÃa cirugÃa | 0.60821 |
| Neck Cancer | 0.605848 |
| siguientes procedimientos | 0.707332 |
| laringectomÃa parcial ayuda | 0.615346 |
| estadio ii | 0.651257 |
| rayos x | 0.611158 |
| pequeñas marcas | 0.606254 |
| estadio ivb | 0.616957 |
| estadio ivc | 0.633063 |
| enlace drugs approved | 0.610885 |
| tratado.ampliar radioterapia | 0.630743 |
| órgano fonador | 0.612088 |
|
| National Cancer Institute | 0.602872 |
| siguientes riesgos | 0.602157 |
| malla ayuda | 0.606514 |
| Instituto Nacional | 0.606325 |
| PDQ Tratamiento | 0.606553 |
| presente sección | 0.60533 |
| Physician Data Query | 0.613617 |
| haz angosto | 0.606683 |
| ganglio linfático mide | 0.979756 |
| laringe dónde | 0.67158 |
| paciente respire | 0.60867 |
| siguientes estadios | 0.629924 |
|
CLICK HERE |
| 3712 |
National Cancer Institute |
Html |
en |
Understanding Precision Medicine in Cancer Treatment |
Precision medicine helps doctors select cancer treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the promise of precision medicine and the role it plays in cancer treatment. |
| cancer treatment | 0.440203 |
| routine care | 0.360336 |
| tumor profiling | 0.359671 |
| medicine clinical trials | 0.414587 |
| type | 0.382285 |
| specific change | 0.357217 |
| new treatments | 0.362099 |
| treatments | 0.484331 |
| research | 0.393932 |
| open trials | 0.357639 |
| rectal cancers | 0.362107 |
| Targeted Cancer Therapies | 0.436947 |
| clinical trials | 0.515013 |
| cancer-causing genetic changes | 0.439486 |
| precision medicine approach | 0.418811 |
| additional genetic changes | 0.428246 |
| cancer-causing changes | 0.378722 |
| researchers | 0.363172 |
| patients | 0.398147 |
| trial staff | 0.356601 |
| cancer types | 0.375159 |
| patient care | 0.366351 |
| different types | 0.361116 |
| Tumor DNA Sequencing | 0.40382 |
| radiation therapy | 0.360769 |
|
| precision medicine | 0.96121 |
| person’s cancer | 0.378533 |
| genetic tests | 0.37503 |
| treatment | 0.491183 |
| precision medicine trials | 0.417382 |
| United States | 0.359831 |
| Cancer Information Service | 0.419259 |
| special lab | 0.36045 |
| targeted drug | 0.368994 |
| genetic understanding | 0.381915 |
| consent form | 0.358985 |
| different people | 0.367337 |
| Research studies | 0.361413 |
| molecular profiling | 0.357183 |
| drugs | 0.382294 |
| specific genetic changes | 0.430567 |
| certain genetic changes | 0.427035 |
| Targeted Therapy | 0.372422 |
| recent advances | 0.370536 |
| genetic changes | 0.967087 |
| specific types | 0.356978 |
| medicine clinical trial | 0.490589 |
| search tool | 0.359567 |
| cancer | 0.783975 |
|
CLICK HERE |
| 16567 |
National Cancer Institute |
Html |
en |
Pembrolizumab Improves Survival for Some Patients with Advanced Non-Small Cell Lung Cancer |
A summary of clinical trial results showing that pembrolizumab improved progression-free and overall survival for patients with advanced non-small cell lung cancer. |
| platinum-based chemotherapy | 0.628936 |
| PD-L1 positive tumors | 0.620887 |
| advanced non-small cell | 0.629259 |
| PD-L1 expression | 0.628117 |
| 1-year overall survival | 0.61848 |
| higher progression-free survival | 0.617259 |
| chemotherapy | 0.698592 |
| time patients | 0.588415 |
| chemotherapy group | 0.668963 |
| immune-mediated adverse events | 0.635601 |
| Dana-Farber Cancer Institute | 0.607312 |
| lung cancer | 0.570765 |
| biomarker. Earlier trials | 0.611797 |
| PD-L1 IHC 22C3 | 0.643265 |
| immune response | 0.572023 |
| PD-L1 protein present | 0.63991 |
| overall survival | 0.629887 |
| immune-mediated deaths | 0.578857 |
| National Cancer Institute | 0.604313 |
| tumor cells | 0.913581 |
| randomized phase | 0.574689 |
| median progression-free survival | 0.633329 |
| PD-L1-expressing tumor cells | 0.661448 |
| immune therapy | 0.577956 |
|
| immune-mediated events | 0.578589 |
| progression-free survival | 0.757999 |
| pembrolizumab group | 0.672943 |
| platinum-based doublet chemotherapy | 0.672126 |
| standard chemotherapy | 0.609699 |
| phase III CheckMate | 0.569846 |
| patients | 0.63251 |
| trial results | 0.620704 |
| previously treated patients | 0.61738 |
| immune cells | 0.61252 |
| adverse events | 0.670445 |
| Dr. Malik | 0.709776 |
| earlier phase trial | 0.627214 |
| metastatic NSCLC | 0.599852 |
| Bruce E. Johnson | 0.59961 |
| survival advantage | 0.568599 |
| untreated advanced NSCLC | 0.642891 |
| New England Journal | 0.615224 |
| severe skin reactions | 0.605442 |
| checkpoint inhibitor pembrolizumab | 0.658193 |
| phase III trial | 0.569107 |
| Pembrolizumab blocks PD-1 | 0.629649 |
| Shakun Malik | 0.582607 |
|
CLICK HERE |
| 16837 |
National Cancer Institute |
Html |
en |
Stanford University — Cancer Translational Nanotechnology Training Program |
The focus of the Stanford University Cancer Nanotechnology Training Center is presented here. |
| interdisciplinary leaders | 0.696815 |
| program director | 0.689314 |
| nanoengineering | 0.558309 |
| M.D. | 0.531791 |
| molecular imaging | 0.829201 |
| faculty | 0.529401 |
| 3-year program | 0.755923 |
| proposed 5-year cycle | 0.860016 |
| Ph.D. | 0.531868 |
| skill sets | 0.677497 |
| trainee progress | 0.671123 |
| Stanford Cancer-Translational Nanotechnology | 0.898203 |
| cancer immunology | 0.705615 |
| molecular pharmacology | 0.687504 |
| gene therapy | 0.664625 |
| cross-disciplinary training | 0.726482 |
| complementary mentors | 0.683687 |
| coursework | 0.53863 |
| biochips | 0.551532 |
| Stanford CNTC website | 0.833637 |
| interdisciplinary researchers | 0.692233 |
| molecular biology | 0.695814 |
| Jianghong Rao | 0.719515 |
| electrical engineering | 0.669775 |
|
| grant application process | 0.806404 |
| cancer research | 0.843254 |
| research advisor | 0.68327 |
| Advisory Committee | 0.662141 |
| Stanford Oncology Clinical | 0.845549 |
| National Cancer Institute | 0.835301 |
| Principal Investigator | 0.706879 |
| postdoctoral trainees | 0.850619 |
| Dean Felsher | 0.699264 |
| Training Committee | 0.688222 |
| clinical translation | 0.702935 |
| materials science | 0.66948 |
| nanomedicine | 0.549348 |
| 3-year training program | 0.964337 |
| hands-on training activities | 0.833884 |
| clinical component | 0.680058 |
| bioengineering | 0.539755 |
| cancer nanotechnology translation | 0.891967 |
| Lecture Series | 0.660584 |
| clinical cancer medicine | 0.877908 |
| entire program | 0.674038 |
| Training Focus | 0.735031 |
| cancer biology | 0.706458 |
| mock grant proposal | 0.812529 |
|
CLICK HERE |